Low-cost tech to restore skull shape after surgery
It is safe, effective and affordable alternative to expensive custom-made implants, biggest advantage being its extremely low cost, about Rs 170, compared to custom 3D-printed PMMA implants that cost Rs 29,000 and titanium implants costing more than Rs 41,500. The study, published in Asian Journal of Neurosurgery, focuses on problems after Retrosigmoid Suboccipital (RMSO) craniotomy—a surgery done to remove tumours from cerebellopontine angle of the brain.
The research team, led by Prof D K Singh and Prof Mohammad Kaif, tested their method on 25 patients over one year. In this technique, PMMA implant is shaped on a regular PVC skull model, sterilised and then fitted into the patient's skull through surgery. TNN
Stay updated with the latest local news from your
city
on
Times of India
(TOI). Check upcoming
bank holidays
,
public holidays
, and current
gold rates
and
silver prices
in your area.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
28 minutes ago
- New Indian Express
Rs 750 crore cancer hospital project works launched in Amaravati
VIJAYAWADA: Hindupur MLA and Basavatarakam Indo American Cancer Hospital & Research Institute (BIACH&RI) Chairman Nandamuri Balakrishna on Wednesday launched construction of a state-of-the-art cancer care campus at Thullur in the Amaravati capital region. Spread across 21 acres, the facility will serve as a Centre of Excellence for cancer treatment, research, and patient-centric care. The foundation for the hospital, a trusted name for over 25 years, was laid in 2019 after the then TDP government allotted land. Construction was delayed due to 'unforeseen circumstances' and alleged negligence by the previous YSRCP government. Balakrishna said the project has now been revived under Chief Minister Nara Chandrababu Naidu, with the State government clearing all hurdles and allotting an additional six acres. Ministers P Narayana, Y Satya Kumar Yadav, MP Kesineni Shivnath (Chinni), MLA Tenali Sravan Kumar, and BIACH&RI board members and Nara Brahmani were present at the ceremony. Balakrishna said the Rs 750 crore first phase will feature a 500-bed facility with precision diagnostics and advanced surgical technology, expected to be operational by 2028. The second phase will add 500 beds, research wings, and specialised departments. Calling the hospital a non-profit, Balakrishna thanked donors, partners, and well-wishers. 'Our mission is to bring hope and healing to every patient, every day,' he said.
Indian Express
2 hours ago
- Indian Express
IIT Delhi, Wadhwani Foundation inaugurate Centre of Excellence in precision & personalised healthcare
The Indian Institute of Technology Delhi (IIT Delhi), has partnered with the Wadhwani Foundation to inaugurate the Centre of Excellence (CoE) in Precision and Personalised Healthcare under the Wadhwani Innovation Network (WIN). The inauguration ceremony was held at IIT Delhi's Research and Innovation Park on August 13 was led by Dr Ajay Kela, CEO and board member, Wadhwani Foundation, and Prof Rangan Banerjee, director, IIT Delhi. The event saw participation of Dr Shivkumar Kalyanaraman, CEO, Anusandhan National Research Foundation; Dr Taruna Madan, Scientist G, Head, Division of Development Research, ICMR; Rajiv Nath, Forum Coordinator, AiMeD; Goutam Bhattacharya, CEO, Life Sciences Sector Skill Development Council; Dr Nikhil Agarwal, MD, FITT, IITD and Gagan Sharma, CEO, Proxmed Australia, mentions the press release. The WIN Centre at IIT Delhi focuses on healthcare technologies, as mentioned in the release, which also added that in Phase 1 of the project, the primary focus is on personalised medicine and rehabilitation, Bio-Imaging and AI as Diagnostic Tools, Assistive Technology for the elderly and Disabled, personalised implants and low-cost wearables, and diagnostic tools. It aims to create a collaborative platform where academia, industry, and government work together to move innovations from lab to market faster, improving patient outcomes and strengthening India's global healthcare leadership. The CoE is part of the Rs 1,400 plus crore investment the Wadhwani Foundation has committed, in collaboration with national partners, to strengthen India's innovation ecosystem. This nationwide initiative — announced by Prime Minister Narendra Modi during the Yugm Innovation Conclave on April 29 — encompasses multiple Centres of Excellence across premier institutions, targeting strategic sectors such as semiconductors, quantum technology, space tech, and advanced computing, alongside healthcare. Prof Rangan Banerjee, Director, IIT Delhi, remarked, 'Through the WIN Centre, IIT Delhi will channelise its expertise in biomedical technologies, AI, and engineering towards delivering tangible healthcare innovations—from precision diagnostics and personalised treatments to affordable medical devices. Our goal is to create solutions that not only address India's healthcare challenges but also set new benchmarks for global impact.'
Time of India
4 hours ago
- Time of India
Apollo Hospitals shares in focus as brokerages hike target prices post strong Q1FY26 results
Apollo Hospitals shares are likely to be in focus on Thursday, August 14, after the company posted a strong set of Q1FY26 results , prompting multiple brokerage firms to raise their target prices for the stock. The healthcare major reported a consolidated net profit of Rs 433 crore for the quarter ended June 30, 2025, marking a 42% year-on-year increase from Rs 305 crore in the same period last year. On a sequential basis, PAT was up 11% from Rs 390 crore in Q4FY25. Finance Value and Valuation Masterclass - Batch 4 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Finance Value and Valuation Masterclass - Batch 3 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals By Vaibhav Sisinity View Program Finance Value and Valuation Masterclass - Batch 2 By CA Himanshu Jain View Program Finance Value and Valuation Masterclass Batch-1 By CA Himanshu Jain View Program Revenue from operations in Q1FY26 rose 15% year-on-year to Rs 5,842 crore compared to Rs 5,086 crore in Q1FY25. Sequentially, revenue grew 4.5% from Rs 5,592 crore in the March quarter. The robust performance was supported by growth across segments, improved specialty mix, and operational efficiency gains. Nuvama: Buy| Target price: Rs 9,010 Nuvama has raised its target price for Apollo Hospitals to Rs 9,010 from Rs 8,635, maintaining a 'Buy' rating. Live Events The brokerage noted strong performance from HealthCo and said sustained execution remains key. It expects hospital growth from H2FY26 through phased bed expansion, higher international patient inflows, and an improved specialty mix. Nuvama also highlighted potential value unlocking from the Keimed merger, front-end restructuring, and a possible listing within 18 months. HealthCo's valuation multiple was raised to 26x from 22x, and FY26E/FY27E EBITDA estimates were increased by 2% and 4%, respectively. Motilal Oswal: Buy| Target price: Rs 9,010 Motilal Oswal also raised its target price to Rs 9,010 from Rs 8,720 while maintaining a 'Buy' rating. The firm cited broad-based growth with EBITDA and PAT beating estimates on cost optimisation and noted that profitability was boosted by lower operating expenses. It highlighted a 14% year-on-year rise in surgical revenues on the back of strong CONGO therapy momentum. HealthCo is on track for cash EBITDA breakeven (excluding ESOP) by Q2FY26/Q3FY26. The brokerage expects 15%, 21%, and 28% CAGR in revenue, EBITDA, and PAT, respectively, over FY25–FY27 and has raised its FY26/FY27 earnings estimates by 7%. Avendus: Buy| Target price: Rs 8,765 Avendus has increased its target price for Apollo Hospitals to Rs 8,765 from Rs 8,515, reiterating a 'Buy' call. The brokerage has advanced the breakeven timeline for the online business EBITDA to FY27 from FY28 earlier. It projects ex-Keimed revenue CAGR at 17% in FY25–FY27, with EBITDA expected at Rs 510 crore and Rs 770 crore for FY26 and FY27, respectively. Offline pharmacy revenue CAGR is also projected at 17%, while existing units' EBITDA CAGR is estimated at 16% in the same period. Avendus factors in the AHCo–Keimed merger in April 2026 and the APL front-end acquisition in April 2027. It expects healthcare services EBITDA CAGR of 14% and AHLL at 22% over FY25–FY27. FY26/FY27 EBITDA estimates have been raised by 4% each, driven by higher AHCo EBITDA, partly offset by new hospital losses. Also read: Zerodha's Nithin Kamath on how a boring, invisible Sebi step brought windfall gains for retail investors ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
